Cure My Disease

Don't miss your cure!

 Log in / Sign up

Antibiotic boosts chemo against tough pancreatic cancer?

NCT ID NCT04523987

Disease control Sponsor: National University Hospital, Singapore Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early study tests whether adding the antibiotic ciprofloxacin to standard chemotherapy can help control metastatic pancreatic cancer. Ten patients who have not had prior treatment will receive the combination. The main goal is to see if the tumors shrink or stop growing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 10 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2019

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Signed informed consent. Written informed consent must be obtained prior to performing any study-related procedures. * Age ≥ 21 years * Histologically or cytologically confirmed, treatment-naïve, locally advanced or metastatic pancreatic adenocarcinoma planned to commence on gemcitabine and nab-paclitaxel chemotherapy. * Patient must have measurable disease as defined by the Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v 1.1 guidelines) * Life expectancy \>3 months * Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 * CrCl ≥ 30 ml/min Exclusion Criteria: * Known hypersensitivity or allergy to ciprofloxacin or other quinolones * On tizanidine or theophylline and unable to stop these medication * Known QTc prolongation (QTc \>500 msec) or torsade de pointes * Presence of Clostridium difficile-associated diarrhea or colitis * Known history of myasthenia gravis * Known G6PD deficiency

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metastatic pancreatic ductal adenocarcinoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metastatic pancreatic ductal adenocarcinoma

Contacts and locations

Locations

  • National University Hospital

    Singapore, Singapore

More trials for these conditions

Other studies related to the condition(s) this trial covers.